Literature DB >> 33890170

Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.

Bernard Cheng1, Alex Villalobos2, Ila Sethi3, William Wagstaff2, James Galt3, David Brandon3, David M Schuster3, Zachary Bercu2, Bill Majdalany2, Nima Kokabi2.   

Abstract

PURPOSE: To compare the efficacies of glass and resin-based Yttrium-90 microspheres by comparing absorbed tumor dose (TD) with both tumor response (TR) and overall survival (OS) in patients with chemorefractory intrahepatic cholangiocarcinoma (ICC).
METHODS: Post-Y90 treatment bremsstrahlung SPECT/CT of 38 consecutive patients receiving 45 treatments (21 resin microspheres, 24 glass microspheres) were analyzed retrospectively. MIM software v6.9.4 (MIM Software Inc, Cleveland, OH) was used to calculate targeted tumors' dose volume histogram. Modified Response Evaluation Criteria in Solid Tumors was used to evaluate tumor response 3 months post-treatment. Kaplan Meier estimation was used for survival analysis. T-test was used to compare the devices on various dosimetric parameters.
RESULTS: Thresholds for TD to predict TR with ≥ 80% specificity were as follows: mean TD (Resin: 78.9 Gy; Glass: 254.7 Gy), maximum TD (Resin: 162.9 Gy; Glass: 591 Gy), minimum TD (Resin: 53.7 Gy; Glass: 149.1 Gy). Microsphere type had no effect on survival from first Y90 (Resin: 11.2 mo; Glass 10.9 mo [p = 0.548]). In patients receiving resin microspheres, mean TD ≥ 75 Gy or maximum TD ≥ 150 Gy was associated with median OS of 20.2 mo compared to 6.5 mo for those receiving less (p = 0.001, 0.002, respectively). For patients treated with glass microspheres, those receiving a mean TD ≥ 150 Gy had a median OS of 14.6 mo vs. 2.6 mo for those receiving less (p = 0.031).
CONCLUSION: TD thresholds predictive of TR and OS differ significantly between glass and resin microspheres. However, microsphere type has no impact on survival in patients with chemorefractory ICC. LEVEL OF EVIDENCE: Level 3, Retrospective Study.

Entities:  

Keywords:  Dosimetry; Intrahepatic cholangiocarcinoma; Y90 radioembolization

Year:  2021        PMID: 33890170     DOI: 10.1007/s00270-021-02834-0

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  3 in total

1.  Using an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing Hepatic 90Yttrium Radioembolization Therapy.

Authors:  Cassidy R Dodson; Colin Marshall; Jared C Durieux; Patrick F Wojtylak; Jon C Davidson; Raymond F Muzic; Arash Kardan
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-04       Impact factor: 2.797

2.  Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.

Authors:  Sander C Ebbers; Caren van Roekel; Manon N G J A Braat; Maarten W Barentsz; Marnix G E H Lam; Arthur J A T Braat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-07       Impact factor: 9.236

Review 3.  Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy.

Authors:  Sedighe Hosseini Shabanan; Nariman Nezami; Mohamed E Abdelsalam; Rahul Anil Sheth; Bruno C Odisio; Armeen Mahvash; Peiman Habibollahi
Journal:  Curr Oncol       Date:  2022-05-24       Impact factor: 3.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.